Works by Banerjee, Arnob

Results: 22
    1
    2

    Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 5, p. 667, doi. 10.1007/s11523-023-00989-z
    By:
    • Miao, Xin;
    • Wu, Liviawati S.;
    • Lin, Shun Xin Wang;
    • Xu, Yan;
    • Chen, Yang;
    • Iwaki, Yuki;
    • Kobos, Rachel;
    • Stephenson, Tara;
    • Kemmerer, Kristy;
    • Uhlar, Clarissa M.;
    • Banerjee, Arnob;
    • Goldberg, Jenna D.;
    • Trancucci, Danielle;
    • Apte, Amit;
    • Verona, Raluca;
    • Pei, Lixia;
    • Desai, Rachit;
    • Hickey, Kathleen;
    • Su, Yaming;
    • Ouellet, Daniele
    Publication type:
    Article
    3
    4

    Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.

    Published in:
    Targeted Oncology, 2022, v. 17, n. 4, p. 433, doi. 10.1007/s11523-022-00893-y
    By:
    • Girgis, Suzette;
    • Lin, Shun Xin Wang;
    • Pillarisetti, Kodandaram;
    • Banerjee, Arnob;
    • Stephenson, Tara;
    • Ma, Xuewen;
    • Shetty, Shoba;
    • Yang, Tong-Yuan;
    • Hilder, Brandi W.;
    • Jiao, Qun;
    • Hanna, Brett;
    • Adams III, Homer C;
    • Sun, Yu-Nien;
    • Sharma, Amarnath;
    • Smit, Jennifer;
    • Infante, Jeffrey R.;
    • Goldberg, Jenna D.;
    • Elsayed, Yusri
    Publication type:
    Article
    5
    6

    Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    EJHaem, 2022, v. 3, n. 1, p. 97, doi. 10.1002/jha2.312
    By:
    • Martin, Thomas;
    • Krishnan, Amrita;
    • Yong, Kwee;
    • Weisel, Katja;
    • Mehra, Maneesha;
    • Nair, Sandhya;
    • Qi, Keqin;
    • Londhe, Anil;
    • Diels, Joris;
    • Crivera, Concetta;
    • Jackson, Carolyn C.;
    • Olyslager, Yunsi;
    • Vogel, Martin;
    • Schecter, Jordan M.;
    • Banerjee, Arnob;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Jagannath, Sundar
    Publication type:
    Article
    7

    Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

    Published in:
    Clinical Drug Investigation, 2022, v. 42, n. 1, p. 29, doi. 10.1007/s40261-021-01100-y
    By:
    • Weisel, Katja;
    • Martin, Thomas;
    • Krishnan, Amrita;
    • Jagannath, Sundar;
    • Londhe, Anil;
    • Nair, Sandhya;
    • Diels, Joris;
    • Vogel, Martin;
    • Schecter, Jordan M.;
    • Banerjee, Arnob;
    • Berdeja, Jesus G.;
    • Nesheiwat, Tonia;
    • Garrett, Ashraf;
    • Qi, Keqin;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Yong, Kwee
    Publication type:
    Article
    8

    Micro-RNA-155 inhibits IFN-γ signaling in CD4.

    Published in:
    European Journal of Immunology, 2010, v. 40, n. 1, p. 225, doi. 10.1002/eji.200939381
    By:
    • Banerjee, Arnob;
    • Schambach, Felix;
    • DeJong, Caitlin S.;
    • Hammond, Scott M.;
    • Reiner, Steven L.
    Publication type:
    Article
    9

    Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 9, p. 690, doi. 10.1016/j.clml.2022.04.025
    By:
    • Weisel, Katja;
    • Krishnan, Amrita;
    • Schecter, Jordan M.;
    • Vogel, Martin;
    • Jackson, Carolyn C.;
    • Deraedt, William;
    • Yeh, Tzu-min;
    • Banerjee, Arnob;
    • Yalniz, Fevzi;
    • Nesheiwat, Tonia;
    • Sanden, Suzy Van;
    • Diels, Joris;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Jagannath, Sundar;
    • Martin, Tom
    Publication type:
    Article
    10

    P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S39, doi. 10.1016/S2152-2650(21)02135-2
    By:
    • Girgis, Suzette;
    • Shun Xin Wang Lin;
    • Pillarisetti, Kodandaram;
    • Verona, Raluca;
    • Vieyra, Diego;
    • Casneuf, Tineke;
    • Fink, Damien;
    • Xin Miao;
    • Yang Chen;
    • Stephenson, Tara;
    • Banerjee, Arnob;
    • Hilder, Brandi;
    • Russell, Jeffery;
    • Smit, Jennifer;
    • Goldberg, Jenna
    Publication type:
    Article
    11

    OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02098-X
    By:
    • Jagannath, Sundar;
    • Berdeja, Jesus G.;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam;
    • Madduri, Deepu;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C.;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Pacaud, Lida;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Usmani, Saad Z.
    Publication type:
    Article
    12

    MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S422, doi. 10.1016/S2152-2650(21)01946-7
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    13

    Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01569-X
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    14

    Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01275-1
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Yi Lin;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    15
    16

    Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 13, p. 2035, doi. 10.1002/cncr.34756
    By:
    • Martin, Thomas G.;
    • Mateos, Maria Victoria;
    • Nooka, Ajay;
    • Banerjee, Arnob;
    • Kobos, Rachel;
    • Pei, Lixia;
    • Qi, Ming;
    • Verona, Raluca;
    • Doyle, Margaret;
    • Smit, Jennifer;
    • Sun, Weili;
    • Trancucci, Danielle;
    • Uhlar, Clarissa;
    • van de Donk, Niels W. C. J.;
    • Rodriguez, Cesar
    Publication type:
    Article
    17

    Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    Current Medical Research & Opinion, 2023, v. 39, n. 1, p. 81, doi. 10.1080/03007995.2022.2139052
    By:
    • Martin, Tom;
    • Usmani, Saad Z.;
    • Schecter, Jordan M.;
    • Roccia, Tito;
    • Jackson, Carolyn C.;
    • Deraedt, William;
    • Yeh, Tzu-min;
    • Banerjee, Arnob;
    • Pacaud, Lida;
    • Garrett, Ashraf;
    • Bartlett, Meaghan;
    • Haltner, Anja;
    • Van Sanden, Suzy;
    • Diels, Joris;
    • Valluri, Satish;
    • Samjoo, Imtiaz A.
    Publication type:
    Article
    18

    Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    Current Medical Research & Opinion, 2021, v. 37, n. 10, p. 1779, doi. 10.1080/03007995.2021.1953456
    By:
    • Martin, Tom;
    • Usmani, Saad Z.;
    • Schecter, Jordan M.;
    • Vogel, Martin;
    • Jackson, Carolyn C.;
    • Deraedt, William;
    • Tian, Hong;
    • Yeh, Tzu-min;
    • Banerjee, Arnob;
    • Pacaud, Lida;
    • Garrett, Ashraf;
    • Haltner, Anja;
    • Cameron, Chris;
    • Van Sanden, Suzy;
    • Diels, Joris;
    • Valluri, Satish;
    • Samjoo, Imtiaz A.
    Publication type:
    Article
    19
    20

    Teclistamab: Mechanism of action, clinical, and translational science.

    Published in:
    CTS: Clinical & Translational Science, 2024, v. 17, n. 1, p. 1, doi. 10.1111/cts.13717
    By:
    • Guo, Yue;
    • Quijano Cardé, Natalia A.;
    • Kang, Lijuan;
    • Verona, Raluca;
    • Banerjee, Arnob;
    • Kobos, Rachel;
    • Chastain, Katherine;
    • Uhlar, Clarissa;
    • Pillarisetti, Kodandaram;
    • Doyle, Margaret;
    • Smit, Jennifer;
    • Haddish‐Berhane, Nahor;
    • Ouellet, Daniele
    Publication type:
    Article
    21
    22